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Abstract 
Background: Permanent neonatal diabetes mellitus (PNDM) is a rare disorder, characterized by uncontrolled 
hyperglycemia diagnosed during the first 6 months of life. In general, PNDM has a genetic origin and most frequently 
it results from heterozygous mutations in KCNJ11, INS and ABCC8 genes. Homozygous or compound heterozygous 
inactivating mutations in GCK gene as cause of PNDM are rare. In contrast, heterozygosis for GCK inactivating muta‑
tions is frequent and results in the maturity‑onset diabetes of young (MODY), manifested by a mild fasting hypergly‑
cemia usually detected later in life. Therefore, as an autosomal recessive disorder, GCK‑PNDM should be considered in 
families with history of glucose intolerance or MODY in first relatives, especially when consanguinity is suspected.
Results: Here we describe two patients born from non‑consanguineous parents within a family. They presented low 
birth weight with persistent hyperglycemia during the first month of life. Molecular analyses for KCNJ11, INS, ABCC8 
did not show any mutation. GCK gene sequencing, however, revealed that both patients were compound heterozy‑
gous for two missense combined in a novel GCK‑PNDM genotype. The p.Asn254His and p.Arg447Gly mutations had 
been inherited from their mothers and fathers, respectively, as their mothers are sisters and their fathers are brothers. 
Parents had been later diagnosed as having GCK‑MODY.
Conclusions: Mutations’ in silico analysis was carried out to elucidate the role of the amino acid changes on the 
enzyme structure. Both p.Asn254His and p.Arg447Gly mutations appeared to be quite damaging. This is the first 
report of GCK‑PNDM in a Brazilian family.
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Background
Permanent neonatal diabetes mellitus (PNDM; OMIM 
#606176) is described as a severe monogenic form of 
diabetes. It is diagnosed during the first 6 months of life 
and requires lifelong treatment with insulin and/or high 
doses of sulfonylurea [1, 2]. In Europeans, the estimated 
incidence rate is about one case per 200,000–250,000 live 
births [3–5]. It is a rare condition associated with defects 
in genes that play major roles in the development, sur-
vival and function of pancreatic beta cells. Mutations in 
about 12 different genes have been identified as responsi-
ble for PNDM [2].
Most frequently, heterozygous mutations in the 
KCNJ11 (OMIM 600937), INS (OMIM 176730) and 
ABCC8 (OMIM 600509) genes are associated with 
PNDM [4]. Despite significant progress in the elucidation 
of the molecular basis of PNDM during last decade, up 
to 40 % of patients remain with unknown etiology [6–8].
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Homozygous or compound heterozygous mutations 
in the GCK gene (OMIM *138079) are considered a rare 
cause of PNDM with an autosomal recessive inheritance 
[9]. Heterozygous inactivating mutations in GCK, how-
ever, cause an autosomal dominant subtype of maturity 
onset diabetes of young (MODY), subtype glucokinase 
(GCK-MODY, previously termed MODY 2; OMIM 
#125851). GCK-MODY is characterized by mild fasting 
hyperglycemia, usually diagnosed later in life [10]. The 
GCK-PNDM phenotype, however, is more severe with 
hyperglycemia manifesting after birth [11–13]. Con-
versely, activating heterozygous GCK mutations have 
been reported as cause of an opposite phenotype, charac-
terized by inappropriate over secretion of insulin despite 
hypoglycemia, called hyperinsulinemic hypoglycemia 
(HH) [14], with a growing number of mutations being 
reported ever since [15]. More than 600 GCK mutations 
have been described in families with PNDM, MODY or 
HH, all of them distributed throughout the gene, with no 
mutation “hot spots” [15].
GCK gene is located in the 7p15.3–p15.1 chromo-
somal region and comprises 12 exons and 11 introns 
which span  ~45,168  bp. The encoded protein has 465 
amino acids with a molecular weight of 52,191 Da and it 
is expressed mainly in the pancreas, liver and brain [16]. 
The presence of tissue-specific promoters allows differen-
tial regulation and transcription of different transcripts 
giving rise to three different-sized exon 1 (a, b, and c). 
Exon 1b and 1c are expressed in the liver while exon 1a is 
expressed in the pancreatic beta cells [17].
Glucokinase (GCK; EC 2.7.1.1), a hexokinase IV or D, 
is a cytoplasmatic enzyme that catalyses the conversion 
of glucose to glucose-6-phosphate in the first reaction 
of the glycolytic pathway. It differs from the other mem-
bers of hexoquinase family of enzymes (hexokinases I, 
II and III or hexokinases A, B, and C) due to its pecu-
liar kinetic properties. Known as the glucose sensor in 
liver and pancreatic beta cells, GCK is a key regulatory 
monomeric enzyme that displays low affinity for glucose 
and a sigmoidal saturation curve for its substrate. In the 
liver, the glucose phosphorylation by GCK promotes gly-
cogen synthesis, while in pancreatic beta cells it results 
in the release of insulin. Both effects, in turn, reduce 
plasma glucose levels [18, 19]. The rate of glucose phos-
phorylation in pancreatic beta cells is directly related to 
the concentration of glucose over a range of physiological 
glucose concentrations (4–15  mmol/L) and it is a rate-
limiting step in the insulin secretion [18].
Pancreatic beta cells are able to regulate the rate of 
glucose metabolism in response to extracellular glucose 
concentration. In order to maintain glucose metabolism 
there must be a rapid equilibration across the plasma 
membrane and GCK glucose phosphorylation [20]. 
Given its central role in the regulation of insulin release, 
it is understandable that inactivating or activating muta-
tions in the GCK gene may cause either hyper or hypo-
glycemia, respectively [21].
Here we describe a non-consanguineous Brazilian 
family with two cases of PNDM diagnosed during first 
months of life, whose parents showed mild fasting hyper-
glycaemia (GCK-MODY) during investigation. GCK 
gene sequencing revealed two missense mutations in 
both index cases: p.Asn254His was inherited from their 
mothers, who are sisters; and p.Arg447Gly, also identified 
in one sibling was inherited from their fathers, who are 
brothers as well.
Case reports
Subject 1
The male proband (Subject III-1, Fig. 1) was referred for 
evaluation at 2  months of age because severe hypergly-
cemia initiated during the 31  days of life [venous glu-
cose level of 700  mg/dL (38.8  mmol/L)]. He was born 
at term by vaginal delivery with a birth weight of 1750 g 
and 42 cm of length, consistent with intrauterine growth 
restriction (IUGR), after a nonsupervisioned pregnancy. 
The mother was drug addict and HIV seropositive. Insu-
lin treatment was initiated at diagnosis with a NPH regi-
men and regular insulin injections twice a day (0.32 U/kg/
day). Further investigation at 8  months of age indicated 
undetectable serum C-peptide level [<0.5 ng/mL (normal 
range 0.8–4  ng/mL)] and negative diabetes-associated 
autoantibodies (i.e., against insulin, islet cell or glutamic 
acid decarboxylase). He is now 10  years old, under a 
basal–bolus insulin therapy, with poor glycemic control 
due to a bad diet compliance and adverse social condi-
tion. The high HbA1c level [8.3 % (67 mmol/mol)−nor-
mal range 3.9–6.1  %] comprove poor glycemic control. 
Mental-motor development is normal and his weight and 
height is within 3rd and 10th percentiles, respectively. 
During investigation, his mother, father and his younger 
brother presented impaired fasting glycaemia (Fig. 1).
Subject 2
The male proband (Subject III-3, Fig. 1), 1 month younger 
cousin of subject 1, was first seen at 1  month of age 
because hyperglycemia diagnosed at 26  days of life. He 
was born at term by caesarean section due to intrauterine 
growth restriction (birth weight, 1550 g; length, 40.5 cm). 
Pregnancy underwent without medical control and his 
mother was also drug addict. At diagnosis he presented 
a high glucose level [1400 mg/dL (77.7 mmol/L)], respira-
tory distress, hyperthermia and dehydration (tachycar-
dia and hypotension). After fluid replacement therapy 
and metabolic support, insulin therapy (with NPH and 
regular insulins—0.4  U/kg/day) was started to control 
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hyperglycemia. On further investigation, the serum 
C-peptide level was likewise undetectable (<0.5  ng/mL) 
and the diabetes-associated autoantibodies were nega-
tive. He is now 10 years old and is receiving a basal-bolus 
insulin therapy. Achieving good glycemic control was 
proving difficult due to the same poor diet compliance 
and social problems, with an elevated haemoglobin A1c 
[HbA1c—13 % (119 mmol/mol)]. He has a good neuro-
motor development and an appropriate growth (weight 
and height at 25th percentile). Laboratory tests revealed 
mild fasting hyperglycemia in both mother and father 
(Fig. 1). His mother had a history of gestational diabetes 
in her last pregnancy, from a new relationship.
Methods
Genomic DNAs from patients, parents and sibling were 
purified from peripheral leukocytes by proteinase K lysis, 
phenol/chloroform extraction, and ethanol precipitation, 
according to standard techniques. Sequencing of genes 
such as KCNJ11, INS and ABCC8 that encode, respec-
tively, Kir6.2, the inward rectifier subunit of the ATP-sen-
sitive potassium channel of the beta cells, preproinsulin 
and SUR1, the regulatory subunit of the ATP-sensitive 
potassium channel of the beta cells had been performed 
as described elsewhere [22–24]. The complete coding 
region for isoform 1 of GCK that is expressed in pancreas 
was sequenced. Fragments containing the ten exons, and 
the 5′ and 3′ untranslated flanking regions were ampli-
fied by polymerase chain reaction (PCR) using specific 
primers designed based on the reference gene sequence 
(ENSG00000106633, http://www.ensembl.org). Inde-
pendent PCR fragments were purified in 1 % agarose gel 
electrophoresis with the wizard SV gel and PCR clean-up 
system (Promega, Madison, WI, USA), and both sense 
and antisense strands were sequenced using the BigDye 
Terminator v3.1 Cycle sequencing kit (Life Technolo-
gies, Grand Island, NY, USA) with the same primers used 
for PCR reactions. The Chromas Lite 2.0 (Technelysium 
Pty Ltd) and CLC Sequence Viewer v.6.8.1 free software 
(CLC bio) were used to analyze and compare sequences 
with the reference GCK sequence. Structural analyses 
were performed using PDB ID: 4DCH—chain A as tem-
plate [25]. The native and mutant models were obtained 
by SWISS MODEL web-served program. Internal con-
tacts were evaluated by STING Millennium (http://www.
cbi.cnptia.embrapa.br) and visualized by PyMol®. Two 
predictive methods to evaluate the effect of the amino 
acid substitutions were used: polymorphism phenotyping 
(PolyPhen) that gives scores ranging from 0 (neutral) to a 
positive (damaging) number and sorting intolerant from 
tolerant (SIFT) whose scores range from 0 (damaging) to 
1 (neutral) [26].
Fig. 1 Pedigree showing inheritance of GCK mutations. Squares with vertical stripes denote males heterozygous for p.Arg447Gly, with GCK‑MODY. 
Circles with horizontal stripes indicate females heterozygous for p.Asn254His, with GCK‑MODY. Probands are indicated by arrows. N/A means data 
not available. Normal range for laboratorial tests: fasting blood glucose 75–99 mg/dl; serum C‑peptide 0.8–4 ng/ml; haemoglobin A1c 3.9–6.1 % 
(19–43 mmol/mol)
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Results
DNA sequence analyses of KCNJ11, INS and ABCC8 
genes did not show any mutation. However, GCK gene 
sequencing revealed two novel transversions: A>C within 
exon 3 and C>G within exon 10 in both probands (Fig. 2). 
The first was also identified in their mothers who are sis-
ters; while the second was identified in their fathers, who 
are brothers, and in the brother of subject 1 (Subject III-
2, Fig.  1). The nucleotide change c.760A>C is predicted 
to cause the substitution of an asparagine by a histidine 
at the residue 254 (p.Asn254His) while the nucleotide 
change c.1340C>G is predicted to cause the substitution 
of an arginine by a glycine at the amino acid residue 447 
(p.Arg447Gly).
The crystal structure of human GCK was solved in 2004 
and revealed that GCK has a large and a small domain 
forming a deep cleft where glucose binds [19]. The bind-
ing-site within this cleft involves residues Glu256 and 
Glu290 in the large domain, Thr168 and Lys169 in the 
small domain and Asn204 and Asp205 in the connect-
ing region I. Induced by glucose binding, GCK under-
goes a global conformational change, with the large and 
small domains getting physically closer and the structure 
assumes a closed active conformation [19].
Residue 254, where the p.Ans254His occurred, is 
located in the large domain within the GCK cleft region, 
two residues away from Glu256 that is critical for glucose 
binding. Structural analyses demonstrated that the native 
Asn254 makes internal hydrogen bond interactions 
with Glu256, Asn231 and Leu58 (Fig. 3a, c). The mutant 
His254 seems to disturb drastically the nearby structure. 
Since it is a bulkier amino acid the distance between 
residue 254 and residues Leu58 and Glu256 increases 
and the interaction with Asn231 is lost. Additionally, it 
established new interactions with residues Thr60, Lys459, 
Cys233, Val207 and Asn204, which is also part of the 
active phosphorylation glucose binding-site (Fig. 3b, d).
Residue 447 is located at the edge of the α-13 helix in 
the C-terminal region of glucokinase that is part of the 
small domain [27]. The native Arg447 makes two hydro-
gen bonds with Val101 and with Leu451, and interacts 
with Tyr215 throught aromatic stacking and hydrophobic 
interactions (Fig.  4a, c). Conversely, the mutant Gly447 
loses both Val101 and Tyr215 interactions, creates a 
new hydrogen bond with Ala450, whether maintains the 
hydrogen bond with Leu451 (Fig. 4b, d).
To estimate functional damage caused by each muta-
tion in silico analysis with different algorithms were per-
formed. For p.Asn254His mutation scores of 0.986 and 
0 were obtained in PolyPhen and SIFT analyses, respec-
tively. Similar results were obtained for p.Arg447Gly 
mutation whose scores were 0.998 and 0 for PolyPhen 
and SIFT, respectively.
Discussion
We describe here two first-cousins with PNDM, diag-
nosed at the first month of life due to severe hypergly-
cemia. They were compound heterozygous for missense 
mutations in GCK gene. To our knowledge, this report 
contains the first description on GCK mutations in Bra-
zilian patients with non-consanguineous parents. Other 
cases of GCK-PNDM have been described in consan-
guineous Arabian and European GCK-MODY families 
and, to date, a total of nine GCK-PNDM related muta-
tions have been reported [11–13, 28–31]. European cases 
of PNDM have been reviewed and verified that com-
plete deficiency of glucokinase is not a common cause of 
PDMN [9, 32].
Initially, KCNJ11, INS and ABCC8 gene screenings 
were performed to investigate the genetic origin of 
Fig. 2 a Electropherogram showing part of GCK exon 7 sequence where the c.760A>C heterozygous transversion leading to p.Asn254His mutation 
occurred. b Electropherogram showing part of GCK exon 10 sequence where the c.1340C>G heterozygous transition leading to p.Arg447Gly muta‑
tion occurred
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PNDM in the present patients, since mutations in those 
genes are most frequently found as cause of the disease 
considering that GCK-PNDM is a rarer condition, espe-
cially when parents are not consanguineous. Since no 
mutations in those genes had been identified, we decided 
to evaluate the glucose fasting level of the parents, who 
were asymptomatic and unwilling to be investigated at 
first. Unexpectedly, they showed a mild fasting hyper-
glycemia when we so decided to perform GCK sequenc-
ing. The p.Asn254His and p.Arg447Gly identified in 
both patients have been inherited from their mothers, 
who were sisters, and their fathers, who were brothers, 
respectively. The p.Arg447Gly was also identified in one 
sibling.
The asparagine in residue 254 is within the large 
domain of GCK [19]. In the wild-type model, this resi-
due interacts with Glu256 maintaining a distance of 2.96 
Å. The residue Glu256 is critical for GCK activity since 
it is part of glucose binding site in the cleft interdomain 
[19]. According to structural analyses, the substitution of 
an asparagine by a histidine at residue 254 modifies the 
interaction and the distance (5.75 Å) with Glu256. The 
disturbance in the glucose binding site conformation 
certainly reflects in all the surroundings. The hydrogen 
bound with Leu58 did not modify significantly the dis-
tance between the residues in the wild-type and mutant 
models (2.79 and 2.81 Å, respectively). In contrast, the 
hydrogen bound with Asn231 was suppressed and five 
new internal interactions can be observed in the mutant 
model, as histidine is a bulky amino acid compared to the 
original asparagine. A novel aromatic interaction with 
Lys459 and four hydrophobic bonds with Cys233, Val207, 
Thr60 and Asn204 can be observed in the mutant. Addi-
tionally, the Asn204 residue is located on connecting 
region I that is also part of the glucose binding-site in 
GCK. Upon solving the crystal structure of human GCK 
by Kamata and colleagues [19] it became well understood 
that this enzyme assumes three structural conformations: 
closed, open (both actives) and super-open form (inac-
tive). When glucose binds to the super-open form, GCK 
Fig. 3 Comparison of normal and mutant glucokinase models at residue 254. a, b Pymol structures for normal asparigine and mutant histidine, 
respectively. Each residue is denoted in red and surrounding residues in orange. Dashed lines represent the distance in Ångström (Å) for internal 
contacts. c, d Graphic results for residue interactions obtained in the STING Millennium analysis. a, c The native Asn254 forms hydrogen bond 
interactions with E256, N231 and L58. b, d The mutant His254 suppresses the interaction with N231, maintains the contact with L58, introduces four 
additional hydrophobic interactions with C233, V207, N204 and T60, creates a new aromatic stacking with K459 and changes the hydrogen bond 
wiht E256 to a charge attractive interaction. Between c and d, color legend for internal interactions provided by BlueStar STING software
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undergoes to a large conformational change to the open 
form. In the presence of ATP, GCK acquire the closed 
conformation, and the phosphorylation of glucose to 
glucose-6-phosphate is carried out. After the reaction 
is complete, GCK returns to its open form in order to 
release glucose-6-phosphate and ADP. If glucose binds to 
the open form during this period, GCK re-enters the cat-
alytic cycle. If this does not happen, GCK returns to the 
inactive super-open form. Therefore, the flexibility of the 
enzyme is critical for its activity. Here we postulate that 
p.Asn254His may compromise the GCK phosphorylating 
potential by affecting its binding-site, since the mutation 
modifies several interactions with surrounding residues 
in this critical region. Moreover, when other internal 
contacts that restrict the enzymatic flexibility are created, 
a consequent damage affecting its activity may occur.
The arginine at codon 447 is described as a compo-
nent of the α-13 helix of human GCK that extends from 
residue Glu443 to Ala460 [27]. The α-13 and α-5 helices, 
within the small domain, play a critical role in the confor-
mational change that occurs between the active and inac-
tive forms of the enzyme [19]. In the closed, active form of 
GCK, the α-13 helix is included in the small domain but in 
the super-open form, the inactive conformation, the α-13 
helix is released from the small domain because of the 
loose structure of connecting region I, in order to facili-
tate its large rotation. Given that the α-13 helix is cru-
cial for the conformational changes observed during the 
enzymatic activation, sequence divergences in this region 
is supposed to disturb its function. The p.Arg447Gly led 
to a new internal contact, a hydrogen bond with Ala450. 
Although the hydrogen bond with Leu451 residue was 
maintained, two other interactions were suppressed. 
Mutations are often observed in this region as activating 
mutations related to HH [33]. However, two heterozy-
gous inactivating mutations in residue 447 (p.Arg447Gln 
and p.Arg447del29) have already been described as 
cause of GCK-MODY [34]. Recently, Capuano et al. [35] 
described the frameshift mutation p.Arg447Glyfs and 
Shammas et  al. [36] reported the missense mutation p. 
Arg447Pro, as cause of GCK-MODY phenotype as well. 
The missense mutation p.Arg447Gly is been reported 
here for the first time, as cause of GCK-MODY in three 
heterozygous members of the family and also as cause of 
GCK-PNDM in association with p.Asn254His mutation, 
described here for the first time as well. The identification 
of GCK mutations in patients with PNDM provides a firm 
diagnosis of the subtype and, as any inherited disorder, 
Fig. 4 Comparison of normal and mutant glucokinase models at residue 447. a, b Pymol structures for normal arginine and mutant glycine, respec‑
tively. Each residue is denoted in red and surrounding residues in blue. Dashed lines represent the distance in Ångström (Å) for internal contacts. c, d 
Graphic results for residue interactions obtained in the STING Millennium analysis. a, c The native Arg447 makes two hydrogen bonds with Val101 
and with Leu451, and interacts with Tyr215 through aromatic stacking and hydrophobic interactions. b, d The mutant Gly447 looses both Val101 
and Tyr215 interactions, creates a new hydrogen bond with Ala450, and maintains the hydrogen bond with Leu451. Between c and d, color legend 
for internal interactions provided by BlueStar STING software
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brings implications for diagnosis and treatment of other 
members in a family. Recently, some authors described 
an improvement in the glycaemic control in response to 
oral sulphonylurea therapy in association with insulin in 
patients with GCK-PNDM, with an increase in both basal 
and stimulate insulin secretion [13, 30]. Besides, efforts to 
replace treatment with insulin by sulfonylurea (as in cases 
of neonatal diabetes caused by mutations in KCNJ11 and 
ABCC8 genes) were not successful since the improvement 
in glycemic control was partial and insulin injections 
could not be stopped.
The discovery of inactivating and activating GCK 
mutations and their functional implications has led to 
important insights into the biochemical GCK activa-
tion and regulation [15] and its central role in glucose 
homeostasis. Specially, mutations in α-13 helix as it is 
the case for p.Arg447Gly encourage the development of 
drugs that specifically target this GCK region and also 
highlights some key interactions between α-13 and 5 that 
may be suitable for drug-induced modulation [36]. Many 
efforts in this area have been done to identify novel phar-
macological agents that could activate glucokinase by a 
similar mechanism to that observed for mutations lead-
ing to GCK-HH. The discovery of several classes of small 
molecular glucokinase activators (GKAs) that showed to 
enhance insulin release and reduce hepatic glucose pro-
duction in mouse model, has been seen as a potential tar-
get for antidiabetic therapy [37]. However, recent clinical 
trials revealed that GKAs lose their efficacy over time and 
their use is associated with high incidence of hypoglyce-
mia as well as dyslipidemia and hepatic steatosis [38].
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